Grufity logoGrufity logo

Bruker Corp Stock Research

BRKR

75.77USD+0.92(+1.23%)Delayed

Market Summary

USD75.77+0.92
Delayed
1.23%

BRKR Stock Price

BRKR RSI Chart

BRKR Valuation

Market Cap

11.1B

Price/Earnings (Trailing)

37.56

Price/Sales (Trailing)

4.4

EV/EBITDA

20.87

Price/Free Cashflow

76.72

BRKR Price/Sales (Trailing)

BRKR Profitability

Operating Margin

51.59%

EBT Margin

16.36%

Return on Equity

26.35%

Return on Assets

8.21%

Free Cashflow Yield

1.3%

BRKR Fundamentals

BRKR Revenue

Revenue (TTM)

2.5B

Revenue Y/Y

3.64%

Revenue Q/Q

10.88%

BRKR Earnings

Earnings (TTM)

296.6M

Earnings Y/Y

28.67%

Earnings Q/Q

10.56%

Price Action

52 Week Range

48.4276.81
(Low)(High)

Last 7 days

3.2%

Last 30 days

6.3%

Last 90 days

13.9%

Trailing 12 Months

15.1%

BRKR Financial Health

Current Ratio

2.31

Debt/Equity

1.22

Debt/Cashflow

0.17

BRKR Investor Care

Dividend Yield

0.26%

Dividend/Share (TTM)

0.2

Buy Backs (1Y)

2.47%

Diluted EPS (TTM)

1.99

Peers (Alternatives to Bruker)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
218.8B
44.9B
1.80% -2.69%
31.44
4.87
14.55% -9.94%
38.9B
6.8B
-7.12% -2.94%
31.04
5.68
8.37% 3.64%
34.8B
4.6B
9.07% -35.87%
-7.89
7.58
1.28% -677.95%
32.3B
3.9B
0.30% 5.82%
37.04
8.24
5.43% 13.46%
11.1B
2.5B
6.34% 15.12%
37.56
4.4
4.67% 7.04%
MID-CAP
2.1B
509.7M
26.37% -5.44%
-14.51
4.11
5.24% -1628.17%
SMALL-CAP
2.2B
128.3M
3.11% -0.62%
-6.93
16.97
-1.69% -73.40%
1.2B
185.3M
-4.53% -36.18%
-6.03
6.51
20.06% 3.42%
394.4M
105.5M
-10.11% -62.94%
-4.08
3.74
-4.55% -67.63%
326.9M
27.8M
-22.54% -54.36%
-2.47
11.76
54.62% -83.06%
255.3M
138.6M
-29.45% -81.04%
-7.6
1.84
32.30% -57.86%
130.5M
113.3M
8.01% -46.55%
-13.71
1.15
-4.68% -3204.17%
123.0M
72.0M
-3.51% -34.52%
-7.46
1.71
6.82% 39.11%
77.7M
42.4M
-38.54% -82.46%
-0.99
1.83
30.40% -43.67%

Financials for Bruker

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.0%2,5312,5062,4762,4582,418
Cost Of Revenue0.0%1,2251,2241,2211,2211,208
Gross Profit1.9%1,3061,2811,2551,2371,210
Operating Expenses2.2%873854846817796
  S&GA Expenses1.9%607596593575561
  R&D Expenses2.3%236231226223221
EBITDA0.6%503500480505-
EBITDA Margin-0.4%0.20*0.20*0.19*0.21*-
Earnings Before Taxes0.4%414412392402394
EBT Margin-0.6%0.16*0.16*0.16*0.16*-
Interest Expenses-20.00----
Net Income7.9%297275274282277
Net Income Margin6.8%0.12*0.11*0.11*0.11*-
Free Cahsflow22.5%145119114176-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets8.2%3,6123,3373,3853,5513,650
  Current Assets3.8%2,1132,0372,0882,2512,472
    Cash Equivalents3.6%6496267238161,068
  Inventory6.8%800750759740710
  Net PPE15.5%487422395404406
  Goodwill19.9%458382396384340
  Current Liabilities5.7%914865818881939
    LT Debt, Non Current5.6%1,2011,1371,1711,2051,222
Shareholder's Equity20.1%1,1269379841,0311,071
  Retained Earnings-1,660----
  Additional Paid-In Capital-238----
Shares Outstanding-0.2%147147148149151
Minority Interest8.2%12.0011.0014.0014.0014.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations13.6%274242196262282
  Share Based Compensation-2.1%28.0028.0027.0021.0017.00
Cashflow From Investing-66.7%-251-150-141-270-192
Cashflow From Financing-1754.6%-41525.00105139319
  Dividend Payments4.9%30.0028.0027.0026.0024.00
  Buy Backs-17.4%265321248226153

Risks for BRKR

What is the probability of a big loss on BRKR?

62.7%


Probability that Bruker stock will be more than 20% underwater in next one year

37.7%


Probability that Bruker stock will be more than 30% underwater in next one year.

5.4%


Probability that Bruker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BRKR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bruker was unfortunately bought at previous high price.

Drawdowns

Returns for BRKR

Cumulative Returns on BRKR

15.3%


10-Year Cumulative Returns

16.1%


7-Year Cumulative Returns

21.4%


5-Year Cumulative Returns

30.2%


3-Year Cumulative Returns

What are the long-term rolling returns for BRKR?

FIve years rolling returns for Bruker.

Annualized Returns

Which funds bought or sold BRKR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-28.23
-125,320
1,532,680
-%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
160,000
714,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-16.7
727,022
10,677,000
0.01%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
243,000
1,087,000
0.01%
2023-02-21
KB FINANCIAL PARTNERS, LLC
unchanged
-
-
-
-%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
reduced
-7.48
281,249
1,745,250
0.05%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
sold off
-100
-2,000
-
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-153,000
-
-%
2023-02-17
Linden Thomas Advisory Services, LLC
new
-
1,086,560
1,086,560
0.31%
2023-02-17
TRUIST FINANCIAL CORP
added
0.49
251,659
1,105,660
-%

1–10 of 47

Latest Funds Activity

Are funds buying BRKR calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BRKR
No. of Funds

Bruker News

MarketBeat

StockNews.com Lowers Bruker (NASDAQ:BRKR) to Buy.

MarketBeat,
13 hours ago

Investor's Business Daily

Nasdaq

Investor's Business Daily

Investor's Business Daily

Schedule 13G FIlings of Bruker

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
t. rowe price investment management, inc.
11.1%
16,368,144
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
7.51%
11,045,016
SC 13G/A
Feb 08, 2023
massachusetts financial services co /ma/
5.1%
7,513,039
SC 13G
Jan 31, 2023
blackrock inc.
7.6%
11,118,621
SC 13G/A
Jan 23, 2023
laukien joerg c
5.1%
7,515,769
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
13.7%
20,854,627
SC 13G/A
Feb 09, 2022
vanguard group inc
7.10%
10,765,626
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
blackrock inc.
7.2%
10,844,554
SC 13G

BRKR Fair Value

Bruker fair value in different scenarios

The table shows the Fair Value estimates for Bruker for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

23.45

-69.05%

28.59

-62.27%

38.17

-49.62%

49.41

-34.79%

57.33

-24.34%
Current Inflation

21.47

-71.66%

25.82

-65.92%

33.85

-55.33%

43.25

-42.92%

49.83

-34.24%
Very High Inflation

19.02

-74.90%

22.48

-70.33%

28.74

-62.07%

36.09

-52.37%

41.19

-45.64%

Historical Bruker Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Bruker

View All Filings
Date Filed Form Type Document
Mar 01, 2023
10-K
Annual Report
Feb 22, 2023
3/A
Insider Trading
Feb 21, 2023
8-K
Current Report
Feb 14, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
8-K
Current Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
SC 13G
Major Ownership Report
Jan 31, 2023
SC 13G/A
Major Ownership Report
Jan 23, 2023
SC 13G
Major Ownership Report

Latest Insider Trading transactions for BRKR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-17
Friend Cynthia M
sold
-62,867
68.26
-921
-
2023-01-05
PACKER RICHARD A
acquired
-
-
1,970
-
2023-01-05
Kastner Marc A
acquired
-
-
1,970
-
2023-01-05
ORNELL JOHN A
acquired
-
-
1,970
-
2023-01-05
Ma Philip
acquired
-
-
1,970
-
2023-01-05
Friend Cynthia M
acquired
-
-
1,970
-
2023-01-05
Perkins Adelene Q
acquired
-
-
1,970
-
2023-01-05
Anderson Bonnie H
acquired
-
-
1,970
-
2023-01-05
Requardt Hermann Fritz
acquired
-
-
1,970
-
2023-01-05
LINTON WILLIAM A
acquired
-
-
1,970
-

1–10 of 50

Frank H. Laukien
7760
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

BRKR Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Total revenue$ 2,530.7$ 2,417.9$ 1,987.5
Total cost of revenue1,225.01,208.31,047.7
Gross profit1,305.71,209.6939.8
Operating expenses:   
Selling, general and administrative607.4561.2468.6
Research and development235.9220.8198.0
Other charges, net29.714.324.9
Total operating expenses873.0796.3691.5
Operating income432.7413.3248.3
Interest and other income (expense), net(18.8)(19.7)(22.5)
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries413.9393.6225.8
Income tax provision116.4113.064.4
Equity in income of unconsolidated investees, net of tax1.00.00.0
Consolidated net income298.5280.6161.4
Net income attributable to noncontrolling interests in consolidated subsidiaries1.93.53.6
Net income attributable to Bruker Corporation$ 296.6$ 277.1$ 157.8
Net income per common share attributable to Bruker Corporation shareholders:   
Basic (in dollars per share)$ 2.00$ 1.83$ 1.03
Diluted (in dollars per share)$ 1.99$ 1.81$ 1.02
Weighted average common shares outstanding:   
Basic (in shares)148.6151.4153.4
Diluted (in shares)149.4152.9154.6
Consolidated net income$ 298.5$ 280.6$ 161.4
Foreign currency translation adjustments (net of tax of $1.4, $2.1 million and $1.2, respectively)(67.4)(77.8)97.4
Derivatives designated as hedging instruments (net of tax of ($13.8) , $12.5 , respectively)44.251.4(75.8)
Pension liability adjustments (net of tax of ($11.8) , ($3.9) and ($1.7) , respectively)45.014.57.5
Comprehensive income320.3268.7190.5
Less: Comprehensive income attributable to noncontrolling interests1.61.04.0
Less: Comprehensive loss attributable to redeemable noncontrolling interest(0.9)(0.1)(0.5)
Comprehensive income attributable to Bruker Corporation319.6267.8187.0
Product   
Total revenue2,109.92,017.31,638.1
Total cost of revenue984.0979.3840.2
Service   
Total revenue414.6393.2343.4
Total cost of revenue240.8228.2206.5
Other   
Total revenue6.27.46.0
Total cost of revenue$ 0.2$ 0.8$ 1.0

BRKR Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 645.5$ 1,068.2
Short-term investments0.0100.0
Accounts receivable, net472.7416.9
Inventories800.1710.1
Assets held for sale1.44.4
Other current assets193.5172.2
Total current assets2,113.22,471.8
Property, plant and equipment, net487.0406.1
Goodwill457.6339.5
Intangible assets, net270.9211.8
Operating lease assets51.259.9
Deferred tax assets76.890.1
Other long-term assets155.170.8
Total assets3,611.83,650.0
Current liabilities:  
Current portion of long-term debt and finance lease obligations18.7112.4
Accounts payable178.4147.4
Customer advances218.0197.5
Other current liabilities499.2481.2
Total current liabilities914.3938.5
Long-term debt1,200.51,221.8
Long-term deferred revenue56.250.2
Deferred tax liabilities62.346.0
Operating lease liabilities34.841.8
Accrued pension45.7104.7
Other long-term liabilities166.2162.2
Commitments And Contingencies
Redeemable noncontrolling interests6.10.2
Shareholders' equity:  
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding at December 31, 2022 and 20210.00.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,389,586 and 174,905,035 shares issued and 147,023,144 and 150,753,687 outstanding at December 31, 2022 and 2021, respectively1.71.7
Treasury stock at cost, 28,366,442 and 24,151,348 shares at December 31, 2022 and 2021, respectively(1,085.0)(820.3)
Additional paid-in capital256.3237.8
Retained earnings1,926.01,659.5
Accumulated other comprehensive income (loss), net of tax14.8(8.2)
Total shareholders' equity attributable to Bruker Corporation1,113.81,070.5
Noncontrolling interests in consolidated subsidiaries11.914.1
Total shareholders' equity1,125.71,084.6
Total liabilities, redeemable noncontrolling interest and shareholders' equity$ 3,611.8$ 3,650.0